Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells
Dysregulation of group 2 innate lymphoid cells has been linked to virus-induced asthma. Fritz and colleagues demonstrate that deficiency in signaling via type I interferons in these cells can lead to dysregulated type 2 immunity during respiratory viral infection. Viral respiratory tract infections...
Saved in:
Published in | Nature immunology Vol. 17; no. 1; pp. 65 - 75 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.01.2016
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Dysregulation of group 2 innate lymphoid cells has been linked to virus-induced asthma. Fritz and colleagues demonstrate that deficiency in signaling via type I interferons in these cells can lead to dysregulated type 2 immunity during respiratory viral infection.
Viral respiratory tract infections are the main causative agents of the onset of infection-induced asthma and asthma exacerbations that remain mechanistically unexplained. Here we found that deficiency in signaling via type I interferon receptor led to deregulated activation of group 2 innate lymphoid cells (ILC2 cells) and infection-associated type 2 immunopathology. Type I interferons directly and negatively regulated mouse and human ILC2 cells in a manner dependent on the transcriptional activator ISGF3 that led to altered cytokine production, cell proliferation and increased cell death. In addition, interferon-γ (IFN-γ) and interleukin 27 (IL-27) altered ILC2 function dependent on the transcription factor STAT1. These results demonstrate that type I and type II interferons, together with IL-27, regulate ILC2 cells to restrict type 2 immunopathology. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 AUTHOR CONTRIBUTIONS C.U.D. and J.H.F. designed the conceptual framework of the study, designed experiments and wrote the paper; C.U.D., C.D.A.M. and B.C.M. designed and performed experiments and analyzed data; M.R. and M.S. performed experiments with human ILC2 cells and helped to design and interpret experiments; A.P.M. and I.L.K. provided H. polygyrus, performed infections and helped to design and interpret experiments; J.P. and S.M.V. provided influenza virus and helped to design and interpret experiments; M.M.E. and D.M. provided STAT4-mutant mice; J.-F.G. provided reagents and expertise for experiments with IL-27; S.T.Q. provided STAT1-deficient BM; B.D.M. provided equipment and expertise for AHR measurements; K.L.M. provided IRF9-deficient BM; A.M.G. provided STAT1- and STAT2-deficient BM; and all authors provided input throughout the study and the writing of the manuscript. |
ISSN: | 1529-2908 1529-2916 |
DOI: | 10.1038/ni.3308 |